The U.S. biopharmaceutical giant is interested in Impact Biomedicine’s fedratinib, a kinase inhibitor that has shown promise in treating myelofibrosis, which is a complex blood cancer.
Under the deal, Celgene will pay $1.1 billion upfront for Impact Biomedicines. If the FDA approves fedratinib, Celgene will pay an additional $1.4 billion to the startup. Additionally, Celgene will make payments to Impact Biomedicine depending on sales of the drug. If fedratonib’s net sales exceed $5 billion, Impact will receive $4.5 billion from Celgene.
More articles on supply chain:
FDA: IV fluid shortage exacerbated by hurricane damage to Puerto Rico is expected to improve
California city could be first in US to use drones to deliver blood
Mold-contaminated antibiotic recalled nationwide: 5 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.